Design, synthesis, and biological evaluation of novel aryl isoxazoles as potential Hsp90 inhibitors

Mina Ardestani, Fariba Keshavarzipour, Maryam Abbasi, Afshin Zarghi, Mahmoud Aghaei, Mehran Ghiaci, Hojjat Sadeghi-Aliabadi

Abstract


Background and purpose: Heat shock protein 90 (Hsp90) is a molecular chaperone critical for the stabilization of numerous oncoproteins, making it a promising target for anticancer drug development. This study aimed to design, synthesize, and evaluate novel 3,5-diarylisoxazole derivatives as potential Hsp90 inhibitors

Experimental approach: A series of 3,5-diarylisoxazole compounds (5R1-6) was designed using molecular docking to predict binding affinity. Compounds were synthesized via cyclization of 4-chloroacetophenone with hydroxylamine hydrochloride, followed by condensation with various aldehydes. Structures were confirmed by melting point, FT-IR, and 1H-NMR spectroscopy. The MTT assay assessed cytotoxicity, and Hsp90 inhibitory activity was evaluated using an Hsp ELISA kit. The stability of the 5R3 compound in the Hsp90 active site was investigated using molecular dynamics simulation.

Findings/Results: All compounds showed favorable binding energies. Compound 5R3 showed the highest binding affinity (ΔG = -7.83 kcal/mol) and the highest cytotoxicity against MCF-7 cells (IC50 = 0.014 μM) and significantly reduced Hsp90 concentration from 5.54 ng/mL (untreated) to 1.56 ng/mL. Furthermore, molecular dynamics simulation studies confirmed the stability of the Hsp90-5R3 complex during a 100 ns simulation.

Conclusion and implications: Compound 5R3 with an electronegative substituent (F) on the aromatic ring showed the highest cytotoxic effect, also decreased the concentration of Hsp90 protein more than others.

Keywords: Hsp90 inhibitor; Isoxazole; Molecular docking; Molecular dynamics simulation; MTT assay. 


Full Text:

PDF

References


Jee H. Size dependent classification of heat shock proteins: a mini-review. J Exerc Rehabil. 2016;12(4):255-259.DOI: 10.12965/jer.1632642.321.

Kregel KC. Heat shock proteins: modifying factors in physiological stress responses and acquired thermotolerance. J Appl Physiol. 2002; 92(5):2177-2186. DOI: 10.1152/japplphysiol.01267.2001.

Schopf FH, Biebl MM, Buchner J. The HSP90 chaperone machinery. Nat Rev Mol Cell Biol. 2017;18(6):345-360. DOI: 10.1038/nrm.2017.20.

Zuehlke AD, Moses MA, Neckers L. Heat shock protein 90: its inhibition and function. Philos Trans R Soc B Biol Sci. 2018; 373(1738):20160527,1-6. DOI: 10.1098/rstb.2016.0527.

Wang M, Shen A, Zhang C, Song Z, Ai J, Liu H, et al. Development of heat shock protein (Hsp90) inhibitors to combat resistance to tyrosine kinase inhibitors through HSP90-kinase interactions. J Med Chem. 2016;59(12):5563-5586. DOI: 10.1021/acs.jmedchem.5b01106.

Bhat R, Tummalapalli SR, Rotella DP. Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors: Miniperspective. J Med Chem. 2014;57(21):8718-8728. DOI: 10.1021/jm500823a.

Ardestani M, Khorsandi Z, Keshavarzipour F, Iravani S, Sadeghi-Aliabadi H, Varma RS. Heterocyclic compounds as Hsp90 inhibitors: a perspective on anticancer applications. Pharmaceutics. 2022;14(10):2220. DOI: 10.3390/pharmaceutics14102220.

Kitson RRA, Moody CJ. Learning from nature: advances in geldanamycin-and radicicol-based inhibitors of Hsp90. J Org Chem. 2013;78(11):5117-5141. DOI :10.1021/jo4002849.

Cherfaoui B, Guo T, Sun H-P, Cheng W-L, Liu F, Jiang F, et al. Synthesis and evaluation of 4-(2-hydroxypropyl) piperazin-1-yl) derivatives as Hsp90 inhibitors. Bioorg Med Chem. 2016;24(11):2423-2432. DOI: 10.1016/j.bmc.2016.03.049.

Hadden MK, Hill SA, Davenport J, Matts RL, Blagg BSJ. Synthesis and evaluation of Hsp90 inhibitors that contain the 1, 4-naphthoquinone scaffold. Bioorg Med Chem. 2009;17(2):634-640. DOI: 10.1016/j.bmc.2008.11.064.

Taldone T, Zatorska D, Patel PD, Zong H, Rodina A, Ahn JH, et al. Design, synthesis, and evaluation of small molecule Hsp90 probes. Bioorg Med Chem. 2011;19(8):2603-2614. DOI: 10.1016/j.bmc.2011.03.013.

Xiao Y, Liu Y. Recent advances in the discovery of novel HSP90 inhibitors: an update from 2014. Curr Drug Targets. 2020;21(3):302-317. DOI: 10.2174/1389450120666190829162544.

Sharp SY, Prodromou C, Boxall K, Powers M V, Holmes JL, Box G, et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther. 2007;6(4):1198-1211. DOI: 10.1158/1535-7163.MCT-07-0149.

Çalışkan B, Sinoplu E, İbiş K, Akhan Güzelcan E, Çetin Atalay R, Banoglu E. Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents. J Enzyme Inhib Med Chem. 2018;33(1):1352-1361. DOI: 10.1080/14756366.2018.1504041.

Trivedi J, Parveen A, Rozy F, Mitra A, Bal C, Mitra D, Sharon A. Discovery of 2-isoxazol-3-yl-acetamide analogues as heat shock protein 90 (HSP90) inhibitors with significant anti-HIV activity. Eur J Med Chem. 2019;183:111699. DOI: 10.1016/j.ejmech.2019.111699.

Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, et al. 4, 5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem. 2008;51(2):196-218. DOI: 10.1021/jm701018h.

Abbasi M, Amanlou M, Aghaei M, Bakherad M, Doosti R, Sadeghi-Aliabadi H. New heat shock protein (Hsp90) inhibitors, designed by pharmacophore modeling and virtual screening: synthesis, biological evaluation and molecular dynamics studies. J Biomol Struct Dyn. 2020;38(12):3462-3473. DOI: 10.1080/07391102.2019.1660216.

Keshavarzipour F, Abbasi M, Khorsandi Z, Ardestani M, Sadeghi-Aliabadi H. Design, synthesis and biological studies of new isoxazole compounds as potent Hsp90 inhibitors. Scientific Reports. 2024;14(1):28017. DOI: 10.1038/s41598-024-79051-5.

Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785-2791. DOI: 1002/jcc.21256.

Bera AK, Kim KH. Full wwPDB X-ray Structure Validation Report. wwPDB. Available at: https://www.wwpdb.org/validation/2017/XrayValidationReportHelp

Azizian H, Bahrami H, Pasalar P, Amanlou M. Molecular modeling of Helicobacter pylori arginase and the inhibitor coordination interactions. J Mol Graph Model. 2010;28(7):626-235. DOI: 10.1016/j.jmgm.2009.12.007.

Makarewicz T, Kaźmierkiewicz R. Molecular dynamics simulation by GROMACS using GUI plugin for PyMOL. J Chem Inf Model. 2013;53(5):1229-1234. DOI: 10.1021/ci400071x.

Makarewicz T, Kaźmierkiewicz R. Improvements in GROMACS plugin for PyMOL, including implicit solvent simulations and displaying results of PCA analysis. J Mol Model. 2016;22(5):109,1-7. DOI: 10.1007/s00894-016-2982-4.

Pronk S, Páll S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics. 2013;29(7): 845-854.‏ DOI: 10.1093/bioinformatics/btt055.

Søndergaard CR, Olsson MH, Rostkowski M, Jensen JH. Improved treatment of ligands and coupling effects in empirical calculation and rationalization of pKa values. J Chem Theory Comput. 2011;7(7): 2284-2295.‏ DOI: 10.1021/ct200133y

Sousa da Silva, Alan W., and Wim F. Vranken. ACPYPE-Antechamber Python parser interface. BMC Res Notes. 2012;5:367,1-8. DOI: 10.1186/1756-0500-5-367.

Lagardère P, Mustière R, Amanzougaghene N, Hutter S, Franetich JF, Azas N, et al. 4-Substituted thieno [3, 2-d] pyrimidines as dual-stage antiplasmodial derivatives. Pharmaceuticals. 2022;15(7):820. DOI: 10.3390/ph15070820.

Ushijima S, Togo H. Metal-free one-pot conversion of electron-rich aromatics into aromatic nitriles. Synlett. 2010;2010(7):1067-1070. DOI: 10.1055/s-0029-1219575.

Johnson L, Powers J, Ma F, Jendza K, Wang B, Meredith E, et al. A reliable synthesis of 3-amino-5-alkyl and 5-amino-3-alkyl isoxazoles. Synthesis (Stuttg). 2013;45(2):171-173. DOI: 10.1055/s-0032-1317935.

Hassanzadeh F, Sadeghi-Aliabadi H, Jafari E, Sharifzadeh A, Dana N. Synthesis and cytotoxic evaluation of some quinazolinone- 5-(4-chlorophenyl) 1, 3, 4-oxadiazole conjugates. Res Pharm Sci. 2019;14(5):408-413. DOI: 10.4103/1735-5362.268201.

Hsanzadeh F, Jafari E, Shojaei F, Sadeghi-aliabadi H. Synthesis and cytotoxic activity evaluation of some new 1, 3, 4-oxadiazole, 1, 3, 4-thiadiazole and 1, 2, 4- triazole derivatives attached to phthalimide. Res Pharm Sci. 2021;16(6):634-642.DOI: 10.4103/1735-5362.327509.

Abbasi M, Amanlou M, Aghaei M, Hassanzadeh F, Sadeghi-Aliabadi H. Identification of new Hsp90 inhibitors: structure based virtual screening, molecular dynamic simulation, synthesis and biological evaluation. Anticancer Agents Med Chem. 2021;21(18):2583-2591. DOI: 10.2174/1871520621666210201101818.

Vilsmeier A, Haack A. Über die Einwirkung von Halogenphosphor auf Alkyl‐formanilide. Eine neue Methode zur Darstellung sekundärer und tertiärer p‐Alkylamino‐benzaldehyde. Ber Dtsch Chem Ges. 1927;60(1):119-122. DOI: 10.1002/cber.19270600118.

Rodrigues FC, Kumar NVA, Hari G, Smith J, Lee K, Johnson M, et al. The inhibitory potency of isoxazole-curcumin analogue for the management of breast cancer: a comparative in vitro and molecular modeling investigation. Chem Pap. 2021;75(6):5995-6008. DOI: 10.1007/s11696-021-01775-9.

Balaji E, HariBabu B, Rao V, Subbaraju G, Nagasree K, Kumar M. Synthesis, screening and docking analysis of Hispolon pyrazoles and isoxazoles as potential antitubercular agents. Curr Top Med Chem. 2019;19(9):662-682. DOI: 10.2174/1568026619666190305124954.

Yin L, Niu C, Liao LX, Dou J, Habasi M, Aisa HA. An isoxazole chalcone derivative enhances melanogenesis in B16 melanoma cells via the Akt/GSK3β/β-catenin signaling pathways. Molecules. 2017;22(12):2077. DOI: 10.3390/molecules22122077.

Taha DE, Mahdi MF, Raauf AMR. Molecular modeling, synthesis, and antiproliferative evaluation of new isoxazole ring linked by Schiff bases and azo bond. J Adv Pharm Technol Res. 2023;14(3):213-219. DOI: 10.4103/japtr.japtr_170_23.

Mohamady S, Ismail MI, Mogheith SM, Attia YM, Taylor SD. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma. Bioorganic Chem. 2020;94:103433.DOI: 10.1016/j.bioorg.2019.103433.

Ngu CP, Sahu R, Shah K, Paliwal D, Sah AK, Prajapati BG. Recent development in synthesis and anticonvulsant activity of promising Schiff base derivatives. J Heterocyclic Chem. 2025;62:1264-1284. DOI: 10.1002/jhet.70073.

Hamed MM, Abou El Ella DA, Keeton AB, Piazza GA, Abadi AH, Hartmann RW et al. 6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines. J Med Chem. 2013;8(9):1495-1504. DOI: 10.1002/cmdc.201300147.

Lasri J, Eltayeb NE, Soliman SM, Ali EMM, Alhayyani S, Akhdhar A. Synthesis, crystal structure, DFT, and anticancer activity of some imine-type compounds via routine Schiff base reaction: an example of unexpected cyclization to oxazine derivative. Molecules. 2023;28(12):4766. DOI: 10.3390/molecules28124766.

Liu J, Wang F, Ma Z, Wang X, Wang Y. Structural determination of three different series of compounds as Hsp90 inhibitors using 3D-QSAR modeling, molecular docking and molecular dynamics methods. Int J Mol Sci. 2011;12(2):946-970. DOI: 10.3390/ijms12020946.

Bakherad Z, Mohammadi-Khanaposhtani M, Sadeghi-Aliabadi H, Rezaei S, Fasihi A, Bakherad M, et al. New thiosemicarbazide-1,2,3-triazole hybrids as potent α-glucosidase inhibitors: design, synthesis, and biological evaluation. J Mol Struct. 2019;1192:192-200. DOI: 10.1016/j.molstruc.2019.04.082.

Chandavaram PS, Maddirala SJ, Vidavalur S, Somaiah N. Design, synthesis and biological evaluation of isoxazole bearing N-arylpyrazole derivatives as anticancer agents. Chem Data Coll. 2022;41:100938. DOI: 10.1016/j.cdc.2022.100938.

Sharp SY, Prodromou C, Boxall K, Powers MV, Holmes JL, Box G, et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther. 2007;6(4):1198-1211. DOI: 10.1158/1535-7163.

Sun J, Lin C, Qin X, Dong X, Tu Z, Tang F, Chen C, Zhang J. Synthesis and biological evaluation of 3,5-disubstituted-4-alkynylisoxozales as a novel class of HSP90 inhibitors. Bioorg Med Chem Lett. 2015;25(16):3129-3134. DOI: 10.1016/j.bmcl.2015.06.009.

Wang X, Song X, Zhuo W, Fu Y, Shi H, Liang Y, et al. Advances in Hsp90 inhibitors for cancer therapy. Eur J Med Chem. 2021;218:113383. DOI: 10.1016/j.ejmech.2021.113383.

Sadeghi-Aliabadi H, Mirian M, Banizaman A, Rezazadeh M, Rahimi F, Sepahi S, Sadeghi-Aliabadi M. Gold nanoparticles from Artemisia absinthium, Morus nigra, and Peganum harmala: biosynthesis, characterization, and their biological evaluations against cancer cells. Res Pharm Sci. 2025;20(4): 485-497. DOI: 10.4103/RPS.RPS_159_23.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.